Par Drugs And Chemicals Limited · NSE:PAR
Par Drugs And Chemicals — Q4 FY2022 Earnings Presentation
16 slides from Par Drugs And Chemicals's earnings presentation, May 14, 2022
Slide 1: Investor Presentation Cover Letter to NSE
("Par DRUGS AND CHEMICALS LIMITED Registered Office : 815, Nilamber Triumph, Gotri-Vasna Road, Vadodara - 390 007. Gujarat ((NOIA). Ph.: +91-265-2991021 / 2991022 Email: admin@pardrugs.com CIN No.: L24117GJ1999PLC035512 _ _ _ _ _ _ www pardrugs com PAR/CS/NSE/2022-23/10 To, Date: 14/05/2022 The Mana
Slide 2: Q4-FY22/FY22 Earnings Presentation
("Par DRUGS AND CHEMICALS LIMITED Q4-FY22/FY22 Earnings Presentation
Slide 3: Company Overview
Company Overview
Slide 4: Company Overview
t ompany 3 Overview (~Par DRUGS ANO CHEMICALS LIMITED Operational Revenues (INR Mn) • Promoted by Mr. Falgun Savani and Mr. Jignesh (~Par DRUGS ANO CHEMICALS LIMITED Savani, Par Drugs and Chemicals Limited (PDCL) was founded in 1982 and is engaged in the development and manufacturing of APIs. 209 19
Slide 5: Key Strengths
4 Key Strengths (~Par DRUGS ANO CHEMICALS LIMITED Diversified Portfolio: The company manufactures the entire range of products in the Antacid segment. The product portfolio presently comprises 28 APIs and 10 Fine Chemicals which are marketed domestically and exported. Global Presence: The Company is
Slide 6: Financial & Operational Highlights
FINANCIAL & OPERATIONAL HIGHLIGHTS
Slide 7: Q4-FY22/FY22 Financial & Operational Highlights
6 Q4-FY22/FY22 Financial & Operational Highlights (~Par Q4-FY22 Financial Highlights Operational Highlights Revenue EBITDA EBITDA Margin • For Q4-FY22, sales grew by around 35% YOY, driven by a INR 221 Mn INR 45 Mn 20.36% sales growth in domestic market of 23% and in export market of 84% YOY. • Marg
Slide 8: Q4-FY22/FY22 Financial Overview
Q4-FY22/FY22 Financial Overview
Slide 9: Quarterly Financial Performance (IND-AS)
8 Quarterly Financial Performance (IND-AS) (~Par Income Statement (INR Mn) Q4-FY22 Q4-FY21 Y-o-Y Q3-FY22 Q-o-Q Income from Operations 221 162 36.4% 169 30.8% Total Expenses 176 119 47.9% 134 31.3% EBITDA 45 43 4.6% 35 28.6% EBITDA Margins (%) 20.36% 26.54% (618) bps 20.71% (35) bps Finance Cost 1 3
Slide 10: Annual Financial Performance
9 Annual Financial Performance (~Par Income Statement (INR Mn) FY22 FY21 Y-o-Y Income from Operations 751 608 23.5% Total Expenses 588 447 31.5% EBITDA 163 161 1.2% EBITDA Margins (%) 21.70% 26.48% (478) bps Finance Cost 5 7 (28.6)% Depreciation 33 28 17.9% Other Income 2 2 - Profit before Extra Ord
Slide 11: Historical Income Statement
10 Historical Income statement (~Par Income Statement (INR Mn) FY19 FY20 FY21 FY22 Income from Operations 463 558 608 751 Total Expenses 381 464 447 588 EBITDA 82 94 161 163 EBITDA Margins (%) 17.71% 16.85% 26.48% 21.70% Finance Cost 20 8 7 5 Depreciation 30 27 28 33 Other Income 1 1 2 2 Profit befo
Slide 12: Balance Sheet
11 Balance Sheet (~Par EQUITIES & LIABILITIES (INR Mn) FY20 FY21 FY22 ASSETS (INR Mn) FY20 FY21 FY22 Shareholder Funds 406 522 599 Non Current Assets 359 352 351 (A) Equity Share Capital 61 61 123 (A) Fixed Assets - - (B) Reserves & Surplus 345 461 476 (i) Tangible Assets 344 299 341 (ii) Capital wo
Slide 13: Financial Highlights
12 Financial Highlights (~Par Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 751 26.48% 608 19.08% 558 21.70% 463 18.87% 17.71% 12.25% 424 16.85% 8.60% 5.40% 3.54% 80 82 94 161 163 25 48 116 92 15 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 FY1
Slide 14: Capital Market Highlights
13 Capital Market Highlights (~Par Price Data (31st March, 2022) INR Shareholding Pattern as on 31st March, 2022 Face Value 10 Market Price 159.75 Public 26% 52 Week High/Low 310.60/131.75 Market Cap (Mn) 1,965 Promoters 52 74% Equity Shares Outstanding (Mn)** 12.3 1 Year Avg Trading Volume (‘000) 4
Slide 15: Disclaimer
14 Disclaimer (~Par Par Drugs and Chemicals Limited: The above Presentation with slides have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connec
Slide 16: Thank You
Thank You
Par Drugs and Chemicals — Q4 FY2022 Earnings Presentation on 6ix